Rilotumumab - Amgen
Alternative Names: AMG-102Latest Information Update: 05 Nov 2023
At a glance
- Originator Amgen
- Developer Amgen; Astellas Pharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Hepatocyte growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Gastric cancer; Glioma; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours
Most Recent Events
- 24 Nov 2014 Discontinued - Phase-II for Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease) in Hong Kong (IV)
- 24 Nov 2014 Discontinued - Phase-II for Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease) in India (IV)
- 24 Nov 2014 Discontinued - Phase-II for Gastric cancer (Combination therapy, Late-stage disease, Metastatic disease) in Singapore (IV)